文献速递造血干细胞移植与细胞治疗

吉西他滨联合顺铂及帕博利珠单抗新辅助治疗肌层浸润性膀胱癌的II期研究

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
PubMed 文献 · J Clin Oncol · 2021-08-24

该II期研究评估吉西他滨、顺铂联合帕博利珠单抗新辅助治疗肌层浸润性膀胱癌的安全性和疗效。39例患者中56%达到病理降期(<pT2N0),36%达到病理完全缓解(pT0N0),主要不良事件为血小板减少、贫血、中性粒细胞减少和低镁血症。结论认为该方案达到主要终点且总体安全。

要点

  • 吉西他滨+顺铂+帕博利珠单抗新辅助治疗使56%患者达到病理降期(<pT2N0)。
  • 36%患者达到病理完全缓解(pT0N0)。
  • 常见不良事件为血小板减少(74%)、贫血(69%)、中性粒细胞减少(67%)和低镁血症(67%)。

核心结论

  • 吉西他滨联合顺铂及帕博利珠单抗新辅助治疗达到主要终点,改善病理降期且总体安全。

研究设计与样本

  • II期研究,纳入39例临床T2-4aN0/XM0肌层浸润性膀胱癌患者,接受4周期吉西他滨+顺铂+帕博利珠单抗新辅助治疗后行根治性膀胱切除术。

主要发现

  • 任何级别最常见不良事件为血小板减少(74%)、贫血(69%)、中性粒细胞减少(67%)和低镁血症(67%)。
  • 1例患者发生帕博利珠单抗相关新发1型糖尿病伴酮症酸中毒,无患者因免疫相关不良事件需使用激素。
  • 临床医生报告的不良事件 consistently 低于患者报告。

关键数值与推荐

  • 主要终点为病理降期(<pT2N0),无效假设率35%,备择假设率55%。
  • 初始6例接受帕博利珠单抗200 mg引导后联合顺铂70 mg/m2和吉西他滨1,000 mg/m2,因毒性改为顺铂35 mg/m2分次给药且无引导。

临床怎么用

  • 该方案可作为肌层浸润性膀胱癌新辅助治疗的选择之一,但需注意血液学毒性和免疫相关不良事件监测。

局限性

  • II期单臂研究,样本量39例,需进一步随机研究验证。
  • 初始治疗方案因毒性调整,可能影响安全性评估。
  • 临床医生与患者报告的不良事件存在差异,可能低估毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of gemcitabine and cisplatin in combination with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical cystectomy (RC) in muscle-invasive bladder cancer. METHODS: Patients with clinical T2-4aN0/XM0 muscle-invasive bladder cancer eligible for RC were enrolled. The initial six patients received lead-in pembrolizumab 200 mg once 2 weeks prior to pembrolizumab 200 mg once on day 1, cisplatin 70 mg/m2 once on day 1, and gemcitabine 1,000 mg/m2 once on days 1 and 8 every 21 days for four cycles. This schedule was discontinued for toxicity and subsequent patients received cisplatin 35 mg/m2 once on days 1 and 8 without lead-in pembrolizumab. The primary end point was pathologic downstaging (< pT2N0) with null and alternative hypothesis rates of 35% and 55%, respectively. Secondary end points were toxicity including patient-reported outcomes, complete pathologic response (pT0N0), event-free survival, and overall survival. Association of pathologic downstaging with programmed cell death ligand 1 staining was explored. RESULTS: Thirty-nine patients were enrolled between June 2016 and March 2020 (72% cT2, 23% cT3, and 5% cT4a). Patients received a median of four cycles of therapy. All patients underwent RC except one who declined. Twenty-two of 39 patients (56% [95% CI, 40 to 72]) achieved < pT2N0 and 14 of 39 (36% [95% CI, 21 to 53]) achieved pT0N0. Most common adverse events (AEs) of any grade were thrombocytopenia (74%), anemia (69%), neutropenia (67%), and hypomagnesemia (67%). One patient had new-onset type 1 diabetes mellitus with ketoacidosis related to pembrolizumab and no patients required steroids for immune-related AEs. Clinicians consistently under-reported AEs when compared with patients. CONCLUSION: Neoadjuvant gemcitabine and cisplatin plus pembrolizumab met its primary end point for improved pathologic downstaging and was generally safe. A global study of perioperative chemotherapy plus pembrolizumab or placebo is ongoing.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rose TL, Harrison MR, Deal AM, et al. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2021. PMID: 34428076. doi:10.1200/JCO.21.01003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。